(GLPG) Galapagos - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.976m USD | Total Return: 27.7% in 12m

Oncology Drugs, Immunology Drugs, Cell Therapy
Total Rating 44
Safety 52
Buy Signal -0.42
Biotechnology
Industry Rotation: +3.6
Market Cap: 1.98B
Avg Turnover: 4.75M USD
ATR: 3.15%
Peers RS (IBD): 14.2
Risk 5d forecast
Volatility30.1%
Rel. Tail Risk-9.22%
Reward TTM
Sharpe Ratio0.61
Alpha9.03
Character TTM
Beta0.392
Beta Downside0.521
Drawdowns 3y
Max DD49.03%
CAGR/Max DD-0.18
EPS (Earnings per Share) EPS (Earnings per Share) of GLPG over the last years for every Quarter: "2021-03": 0.14, "2021-06": -0.98, "2021-09": -0.99, "2021-12": 0.25, "2022-03": -0.2, "2022-06": -0.29, "2022-09": 0.33, "2022-12": -3.16, "2023-03": 0.3852, "2023-06": 0.08, "2023-09": 0.39, "2023-12": 2.39, "2024-03": 1.4, "2024-06": 0.14, "2024-09": -0.83, "2024-12": 0.3023, "2025-03": -2.45, "2025-06": -1.58, "2025-09": -3.54, "2025-12": 12.2742, "2026-03": 0,
EPS CAGR: 2.26%
EPS Trend: 2.9%
Last SUE: 0.02
Qual. Beats: 0
Revenue Revenue of GLPG over the last years for every Quarter: 2021-03: 113.891, 2021-06: 139.772, 2021-09: 64.194, 2021-12: 166.988, 2022-03: 136.347, 2022-06: 137.609, 2022-09: 136.203, 2022-12: 95.12, 2023-03: 58.574, 2023-06: 149.953, 2023-09: 120.027, 2023-12: -209.124, 2024-03: 62.432, 2024-06: 77.873, 2024-09: 59.849, 2024-12: 75.495, 2025-03: 74.977, 2025-06: 65.288, 2025-09: 71.161, 2025-12: 900.774, 2026-03: null,
Rev. CAGR: 65.45%
Rev. Trend: 3.9%
Last SUE: 4.00
Qual. Beats: 1
Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: GLPG Galapagos

Galapagos NV is a biotechnology company based in Belgium. It focuses on developing oncology and immunology medicines for the US and European markets.

The companys pipeline includes several drug candidates. GLPG3667 has completed Phase 1b trials. GLPG5101, GLPG5201, and GLPG5301 are all CAR-T cell therapy candidates in Phase 1/2 trials for various blood cancers. CAR-T cell therapies are a rapidly developing area within oncology, offering personalized treatment approaches.

Galapagos operates under a business model common in the biotechnology sector, involving extensive research and development, often leading to collaboration agreements for further development and commercialization. It currently has partnerships with Gilead Sciences and AbbVie.

Further research on ValueRay can provide detailed financials and competitive analysis.

Headlines to Watch Out For
  • Pipeline drug trial results significantly impact stock valuation
  • Regulatory approvals for new therapies drive revenue growth
  • Collaboration milestones with Gilead and AbbVie boost income
  • Research and development expenses affect profitability
  • Competition in oncology and immunology markets impacts sales
Piotroski VR‑10 (Strict) 3.5
Net Income: 320.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.08 > 0.02 and ΔFCF/TA 0.41 > 1.0
NWC/Revenue: 263.0% < 20% (prev 1.09k%; Δ -826.9% < -1%)
CFO/TA -0.07 > 3% & CFO -251.7m > Net Income 320.9m
Net Debt (-75.7m) to EBITDA (292.1m): -0.26 < 3
Current Ratio: 20.15 > 1.5 & < 3
Outstanding Shares: last quarter (65.9m) vs 12m ago -1.43% < -2%
Gross Margin: 56.02% > 18% (prev 0.52%; Δ 5.55k% > 0.5%)
Asset Turnover: 29.50% > 50% (prev 6.67%; Δ 22.83% > 0%)
Interest Coverage Ratio: -7.88 > 6 (EBITDA TTM 292.1m / Interest Expense TTM 25.1m)
Altman Z'' 8.61
A: 0.86 (Total Current Assets 3.08b - Total Current Liabilities 152.8m) / Total Assets 3.41b
B: 0.06 (Retained Earnings 210.5m / Total Assets 3.41b)
C: -0.05 (EBIT TTM -198.0m / Avg Total Assets 3.77b)
D: 2.97 (Book Value of Equity 507.3m / Total Liabilities 170.6m)
Altman-Z'' Score: 8.61 = AAA
Beneish M -1.77
DSRI: 0.15 (Receivables 51.9m/88.1m, Revenue 1.11b/275.6m)
GMI: 0.93 (GM 56.02% / 52.09%)
AQI: 0.44 (AQ_t 0.07 / AQ_t-1 0.16)
SGI: 4.03 (Revenue 1.11b / 275.6m)
TATA: 0.17 (NI 320.9m - CFO -251.7m) / TA 3.41b)
Beneish M-Score: -1.77 (Cap -4..+1) = CCC
What is the price of GLPG shares? As of April 06, 2026, the stock is trading at USD 29.42 with a total of 176,233 shares traded.
Over the past week, the price has changed by +2.01%, over one month by -11.86%, over three months by -10.14% and over the past year by +27.69%.
Is GLPG a buy, sell or hold? Galapagos has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell GLPG.
  • StrongBuy: 0
  • Buy: 0
  • Hold: 4
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the GLPG price?
Wallstreet Target Price 32.8 11.5%
Analysts Target Price 32.8 11.5%
GLPG Fundamental Data Overview as of 06 April 2026
Market Cap EUR = 1.71b (1.98b USD * 0.8664 USD.EUR)
P/E Trailing = 5.2442
P/E Forward = 303.0303
P/S = 1.7764
P/B = 0.5179
Revenue TTM = 1.11b EUR
EBIT TTM = -198.0m EUR
EBITDA TTM = 292.1m EUR
Long Term Debt = 6.92m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.73m EUR (from shortTermDebt, last quarter)
Debt = 12.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.7m EUR (from netDebt column, last quarter)
Enterprise Value = -1.27b EUR (1.71b + Debt 12.1m - CCE 3.00b)
Interest Coverage Ratio = -7.88 (Ebit TTM -198.0m / Interest Expense TTM 25.1m)
EV/FCF = 4.79x (Enterprise Value -1.27b / FCF TTM -265.5m)
FCF Yield = 20.86% (FCF TTM -265.5m / Enterprise Value -1.27b)
FCF Margin = -23.87% (FCF TTM -265.5m / Revenue TTM 1.11b)
Net Margin = 28.85% (Net Income TTM 320.9m / Revenue TTM 1.11b)
Gross Margin = 56.02% ((Revenue TTM 1.11b - Cost of Revenue TTM 489.1m) / Revenue TTM)
Gross Margin QoQ = 48.95% (prev 84.76%)
 Tobins Q-Ratio = -0.37 (set to none) (Enterprise Value -1.27b / Total Assets 3.41b)
 Interest Expense / Debt = 6.83% (Interest Expense 826k / Debt 12.1m)
Taxrate = 0.09% (666k / 783.2m)
NOPAT = -197.8m (EBIT -198.0m * (1 - 0.09%)) [loss with tax shield]
Current Ratio = 20.15 (Total Current Assets 3.08b / Total Current Liabilities 152.8m)
Debt / Equity = 0.00 (Debt 12.1m / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = -0.26 (Net Debt -75.7m / EBITDA 292.1m)
 Debt / FCF = 0.29 (negative FCF - burning cash) (Net Debt -75.7m / FCF TTM -265.5m)
 Total Stockholder Equity = 2.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.51% (Net Income 320.9m / Total Assets 3.41b)
RoE = 11.16% (Net Income TTM 320.9m / Total Stockholder Equity 2.88b)
RoCE = -6.87% (EBIT -198.0m / Capital Employed (Equity 2.88b + L.T.Debt 6.92m))
 RoIC = -7.14% (negative operating profit) (NOPAT -197.8m / Invested Capital 2.77b)
 WACC = 7.36% (E(1.71b)/V(1.72b) * Re(7.36%) + D(12.1m)/V(1.72b) * Rd(6.83%) * (1-Tc(0.00)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
 [DCF] Fair Price = unknown (Cash Flow -265.5m)
 EPS Correlation: 2.89 | EPS CAGR: 2.26% | SUE: 0.02 | # QB: 0
Revenue Correlation: 3.90 | Revenue CAGR: 65.45% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-6.22 | Chg7d=-5.645 | Chg30d=-5.645 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=-6.12 | Chg7d=-3.977 | Chg30d=-3.493 | Revisions Net=+0 | Growth EPS=-160.0% | Growth Revenue=-85.9%
EPS next Year (2027-12-31): EPS=-1.24 | Chg7d=-0.538 | Chg30d=-0.538 | Revisions Net=+0 | Growth EPS=+79.8% | Growth Revenue=-2.6%
[Growth] Implied Growth Rate = -11.1% (Discount Rate 7.9% - Earnings Yield 19.1%)
[Growth] Growth Spread = -48.8% (Analyst -59.9% - Implied -11.1%)
External Resources
Dataroma Stockcircle